433 related articles for article (PubMed ID: 26726907)
1. Cellular immune responses towards regulatory cells.
Larsen SK
Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
[TBL] [Abstract][Full Text] [Related]
2. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
3. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells in tumor immunity.
Nishikawa H; Sakaguchi S
Int J Cancer; 2010 Aug; 127(4):759-67. PubMed ID: 20518016
[TBL] [Abstract][Full Text] [Related]
5. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
6. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
7. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
8. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
9. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.
Mousavi-Niri N; Naseroleslami M; Hadjati J
Hum Vaccin Immunother; 2019; 15(3):620-624. PubMed ID: 30633616
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells in cancer immunotherapy.
Nishikawa H; Sakaguchi S
Curr Opin Immunol; 2014 Apr; 27():1-7. PubMed ID: 24413387
[TBL] [Abstract][Full Text] [Related]
11. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of Foxp3-specific spontaneous immune responses.
Larsen SK; Munir S; Woetmann A; Frøsig TM; Odum N; Svane IM; Becker JC; Andersen MH
Leukemia; 2013 Dec; 27(12):2332-40. PubMed ID: 23812418
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance.
Luckey U; Schmidt T; Pfender N; Romer M; Lorenz N; Martin SF; Bopp T; Schmitt E; Nikolaev A; Yogev N; Waisman A; Jakob T; Steinbrink K
J Allergy Clin Immunol; 2012 Sep; 130(3):781-797.e11. PubMed ID: 22935591
[TBL] [Abstract][Full Text] [Related]
14. Tolerogenic dendritic cells suppress murine corneal allograft rejection by modulating CD28/CTLA-4 expression on regulatory T cells.
Yan F; Cai L; Hui Y; Chen S; Meng H; Huang Z
Cell Biol Int; 2014 Jul; 38(7):835-48. PubMed ID: 24604878
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Cell Res; 2017 Jan; 27(1):109-118. PubMed ID: 27995907
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
17. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
18. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
19. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
Wada J; Yamasaki A; Nagai S; Yanai K; Fuchino K; Kameda C; Tanaka H; Koga K; Nakashima H; Nakamura M; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2008; 28(4C):2401-8. PubMed ID: 18751426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
